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ABSTRACT 
The aim of this study was to compare the effect of intravitreal diclofenac, a non-steroidal anti-inflammatory drug 
(NSAID), with that of bevacizumab, a well-known anti-vascular endothelial growth factor (VEGF) drug, in the treatment of 
diabetic macular edema (DME). Diclofenac was chosen in this study because it has both features of NSAIDs and 
corticosteroids by inhibiting the cyclooxygenase (COX) and lipoxygenase pathways, respectively. In this non-randomized 
comparative interventional case series, 64 eyes from 32 patients with bilateral naïve DME were selected and every eye 
was randomly assigned to intravitreal injection of bevacizumab (IVB) or diclofenac (IVD). After exclusion of some patients 
because of short follow-up duration or less than two intravitreal injections, finally, 52 eyes from 26 patients were 
analyzed. Of those, 26 eyes received 500 µg/0.1 mL IVD and 26 eyes received 1.25 mg IVB. After 6 months of follow-up, 
the results indicated that visual acuity was significantly improved from 0.50 ± 0.13 in IVB and 0.52 ± 0.12 LogMAR in IVD 
at baseline to 0.2 ± 0.1 and 0.29 ± 0.07, respectively. Central macular thickness (CMT) and macular volume were 
measured based on spectral-domain optical coherence tomography (OCT) at month 1, 3, and 6. Both groups showed a 
significant reduction in CMT and macular volume from baseline but there was no significant difference between the IVB 
and IVD groups. Interestingly, IVD, but not IVB, decreased intraocular pressure (IOP), which is a desirable effect. There 
was no serious complication due to injections. This study sheds light into the long-term effects of NSAIDs and may 
support the idea that inflammation suppression by NSAIDs may have the same results as anti-VEGF administration. 
KEY WORDS 
Diclofenac; Bevacizumab; Diabetic Macular Edema; Intravitreal Injection; Anti-inflammatory Agents 
©2017, Med Hypothesis Discov Innov Ophthalmol. 
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial 3.0 
License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial 
purposes from the material, as long as the author of the original work is cited properly. 
 
Correspondence to: 
Razieh Mahmoudzadeh MD, Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, South Kargar Street, Qazvin 
Square, Tehran 13366, Iran. Tel: +989141638918, Email: razieh.mah@gmail.com
INTRODUCTION 
As diabetes mellitus progress, diabetic macular edema 
(DME) can develop at any time of disease. DME 
represents one of the most important causes of vision 
loss in patients with diabetes [1]. There are different 
treatment strategies for DME. Recently, intravitreal 
injection of anti-vascular endothelial growth factor 
(VEGF) drugs has become very popular. Many studies 
have investigated the effect of ranibizumab and 
bevacizumab on diabetic retinopathy, especially DME [2, 
3]. Corticosteroids are another class of well-known 
agents used in intravitreal injections in DME cases [4]. 
DME is the result of different pathophysiological 
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pathways including angiogenesis and prostaglandin-
induced inflammation [5, 6]. Anti-angiogenic agents such 
as ranibizumab and bevacizumab are used to inhibit 
VEGF, and triamcinolone is used to suppress 
prostaglandin-induced inflammation. Non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit the biosynthesis of 
prostaglandins and have emerged as a new possible 
treatment for DME [7, 8]. The inflammatory response 
responsible for initiation of DME causes the release of 
arachidonic acid from cell membrane phospholipids. 
Arachidonic acid turns into prostaglandins (PGs) and 
thromboxanes by means of cyclooxygenase enzymes 
(COX1 and COX2) and into leukotrienes by means of 5-
lypoxygenase enzymes. The interesting point about 
prostaglandins is their potency for induction of 
angiogenesis. One study on cultured Müller cells showed 
that PGs induce the expression of VEGF. NSAIDs, which 
are potent COX inhibitors and anti-inflammatory agents, 
can have antiproliferative and antiangiogenic effects as 
well [9]. Another mechanism that may explain the 
antiangiogenic properties of NSAIDs is the inhibition of 
COX, which in turn reduces PGE1 and PGE2 production. 
This effect can induce vascular regression in chronic 
granulomatous inflammation [10, 11]. Although 
corticosteroids are thought to potently reduce 
inflammation by inhibiting two pathways simultaneously 
(the COX and 5-lypoxygenase pathways), NSAIDs have 
less adverse side effects than corticosteroids. These side 
effects include increased intraocular pressure (IOP) and 
cataract formation in patients with diabetics who are 
more vulnerable to increased IOP and cataract formation 
because of glucose fluctuations [12, 13]. On the other 
hand, injection of corticosteroids needs to be repeated 
quickly because of the short-term outcomes, which in 
turn increases the chance of adverse side effects [14, 15]. 
Another desirable characteristic of NSAIDs is tumor 
necrosis factor (TNF)-alpha suppression, which may 
inhibit early diabetic retinopathy progression [7]. Topical 
usage of NSAIDs is limited by inappropriate delivery to 
the posterior segment because of the blood–aqueous 
barrier. Intravitreal delivery of NSAIDs could enhance 
drug concentration in the posterior segment, especially 
in inflammatory diseases such as DME and age-related 
macular degeneration (AMD) [16]. Diclofenac sodium in a 
member of the NSAID family that can inhibit both the 
COX and lipoxygenase pathways, making it as potent an 
agent as any corticosteroid, with the advantage of not 
having those unwanted side effects [17]. Intravitreal 
injection of diclofenac sodium (IVD) is effective in 
inflammatory retinal diseases such as retinal vein 
occlusions, AMD, uveitic CME, and DME [18, 19]. There 
are a limited number of studies on IVD effects in DME. 
However, recently, the number of studies has grown and 
a small, randomized trial in patients with DME disclosed 
that IVD has similar therapeutic outcomes to intravitreal 
triamcinolone injections [17]. Ketorolac is another 
member of the NSAID family that has promising results in 
the treatment of DME, as reported in some case series 
[20, 21]. The aim of this study was to compare the visual 
and anatomical outcomes of IVD with those of 
intravitreal injection of bevacizumab (IVB). IVD is a safer 
choice for intravitreal injections. This study aimed to 
investigate this effect in patients with DME who were 
followed up in the long term. 
MATERIALS AND METHODS 
This non-randomized comparative interventional case 
series was conducted in Tehran University of Medical 
Sciences from December 2015 to May 2016. Ethical 
approval number by review board/ethics committee of 
the Ophthalmic Research Center of Tehran University of 
Medical Sciences was Rc-9305-23. All the patients who 
participated in the study signed an informed consent 
form before beginning the study. A separate informed 
consent form about probable complications of 
intravitreal injections was signed by all patients before 
entering the study. Sixty-four eyes from 32 patients with 
bilateral naïve DME were enrolled in the study. The 
inclusion criteria were based on the Early Treatment 
Diabetic Retinopathy Study (ETDRS) definition of clinically 
significant macular edema with foveal involvement [22]. 
Exclusion criteria were any prior panretinal or focal laser 
photocoagulation, intraocular surgery or any type of 
intraocular injections before this study, glaucoma, visual 
acuity (VA) of 20/40 or better, VA of 20/200 or worse, iris 
neovascularization, vitreomacular traction or uveitis, 
proliferative diabetic retinopathy, severe ischemic 
maculopathy (large irregular foveal avascular zones on 
fluorescein angiography with distinct areas of capillary 
nonperfusion within 1 disc diameter of the foveal 
center), any other cause of macular edema, significant 
media opacity, and any other associated macular 
diseases. The other exclusion criteria were a total follow-
up of less than 6 months and a total number of 
intravitreal injections less than 2 in 6 months of follow-
up, which resulted in exclusion of six patients. At the end 
of the study, 52 eyes from 26 patients were analyzed. All 
the patients underwent baseline blood testing to 
determine the metabolic control status including 
glycated hemoglobin (HbA1c), low-density lipoprotein 
(LDL), high-density lipoprotein (HDL), and triglyceride 
(TG). All included eyes underwent a complete baseline 
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ophthalmic examination including best-corrected visual 
acuity (BCVA), IOP evaluation, slit-lamp biomicroscopy, 
and fundus photography. Measurement of central 
macular thickness (CMT), central macular volume, and 
macular volume was performed by using spectral-domain 
optical coherence tomography (OCT) (Heidelberg 
Engineering, Vista, California, USA). BCVA was evaluated 
by Snellen charts and was recorded in the logarithm of 
the minimum angle of resolution (logMAR) scale. Each 
eye of a patient was randomly assigned to one of two 
study groups: in the IVD group, each eye received 500 
µg/0.1 mL of diclofenac sodium (Troge Medical GMBH, 
Hamburg, Germany) diluted with balanced salt solution 
intravitreally with a 27-gauge needle through the 
superotemporal quadrant; in the IVB group, each eye 
received 1.25 mg/0.05 mL of bevacizumab (Avastin; 
Genentech Inc., South San Francisco, CA, USA (made for 
F. Haffmann-La Roche, Ltd., Basel, Switzerland)), which 
was injected with through the superotemporal quadrant 
with a 27-gauge needle. All injections were performed 
under sterile conditions using Betadine 5% (applied two 
times, separated by 5 minutes) and anesthetic eye drops 
(two times, 3 minutes apart) with insertion of a lid 
speculum. The study drugs were injected at baseline and 
then every 1 to 1.5 months unless visual acuity was 
20/20 or there was no improvement or worsening in 
response to the past two injections. Two examinations 
were done for each eye to check mostly the anterior 
chamber reaction and IOP rise on day 1 and 7 after the 
first injections. Complete ophthalmologic examination 
was performed at months 1, 3, and 6 after intervention. 
OCT was repeated at months 1, 3, and 6 and central 
retinal thickness was measured in a circle of 3 mm in 
diameter centered on the fixation point. Macular volume 
was measured, too. The primary outcome measure was 
the change in best-corrected logMAR. CMT changes and 
central macular volume as reported in OCT prints were 
the secondary outcome measures. No severe injection-
related complication was observed during the study 
period. Ocular inflammation other than endophthalmitis 
that was in form of anterior chamber reaction was 
observed in two eyes in the IVB group and one eye in the 
IVD group, which was controlled by topical 
corticosteroids. All procedures were run by staff 
members other than the study investigators. Skilled 
examiners measured refraction and BCVA and performed 
OCT at baseline and at each study visit. The examiners 
were masked both to the randomization and to the 
findings of earlier measurements. Patients and 
investigators were not informed of randomization and 
details of IVB and IVD treatment data. 
Statistical analysis was performed with SPSS software 
(version 19; SPSS, Inc., Chicago, IL). Mean ± standard 
deviation (SD), median (interquartile range), range, and 
frequency (percent) were used for descriptive purposes. 
Paired samples t-test and Wilcoxon test were done for 
comparing the values with the baseline within each 
treatment group. Mann–Whitney and paired t-test were 
used to compare variables between groups. Analysis of 
covariance (ANCOVA) and ordinal logistic regression was 
used to adjust for the baseline differences. P values less 
than 0.05 were considered as statistically significant 
RESULTS 
Fifty-two eyes (26 right eyes and 26 left eyes) from 26 
patients with bilateral DME were analyzed. The mean age 
of the patients was 60.1 years (range 53 to 66 years). 
Eighteen were men and 34 were women. Fifteen patients 
had moderate non-proliferative diabetic retinopathy 
(NPDR) and 37 patients had severe NPDR. Table 1 
summarizes the baseline demographic and metabolic 
control characteristics of both groups at baseline. Table 2 
compares visual acuity and macular OCT variables 
including CMT and macular volume between the IVB and 
IVD groups. No significant difference was detected 
between the two groups at baseline. 
Before intervention, the BCVA in the IVB group was 0.50 
± 0.13 logMAR. The BCVA in the IVD group was 0.52 ± 
0.12 logMAR and the difference between groups was not 
statistically significant (P = 0.540). After 6 months, the 
BCVA improved significantly in both groups (Fig 1); it was 
0.2 ± 0.1 in the IVB group and 0.29 ± 0.07 in the IVD 
group, which was statistically significant based on t-test. 
At 1, 3, and 6 months of follow-up, there was no 
significant difference between BCVA of the IVB and IVD 
groups (P > 0.05) (Table 3). 
At 6 months of follow-up, 12 eyes (23.1%) had received 
two injections, 32 eyes (61.5%) had received three 
injections, and eight eyes (15.4%) had received four 
injections; there was no significant difference between 
the IVB and IVD groups (Fig 2). 
To examine the role of baseline variables on final BCVA, 
we performed a multivariate linear regression analysis 
(Table 4). 
 
 
 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2017; 6(3)  
 
70 INTRAVITREAL BEVACIZUMAB AND DICLOFENAC IN DIABETIC MACULAR EDEMA 
 
 
Table 1: Demographics and Clinical Data of the Enrolled Patients 
Variable Value 
Age (years) 60.1 ± 6.7 
Sex  
Male 18 (34.6%) 
Female 34 (65.4%) 
Diabetic retinopathy stage  
Moderate NPDR 15 (28.8%) 
Severe NPDR 37 (71.2%) 
Metabolic control features  
HbA1c (mg/dL) 7.8 ± 1.2 
LDL (mg/dL) 121.3 ± 23.9 
HDL (mg/dL) 40.1 ± 7.4 
TG (mg/dL) 181.8 ± 82.1 
Data in table are presented as mean ± SD or No (%). 
 
Table 2: Comparison of Visual Acuity and Macular Optical Coherence Tomography (OCT) Variables between the Two Groups 
Variable IVB (n = 26) IVD (n = 26) p-value* 
BCVA (logMAR) 0.50 ± 0.13 0.52 ± 10 0.540 
Central macular thickness (µm) 416.8 ± 116.2 439.2 ± 94.4 0.533 
Macular volume (mm
3
) 10.8 ± 1.23 10.91 ± 1.41 0.411 
Central macular volume (mm
3
) 0.34 ± 0.09 0.37 ± 0.12 0.736 
* Based on a t-test, IVB = intravitreal bevacizumab, IVD = intravitreal diclofenac, logMAR = logarithm of the minimum angle of resolution 
 
 
Figure 1: Change in Best-Corrected Visual Acuity (BCVA) after 6 Months in Each Group 
 
Table 3: Comparison of Visual Acuity in Follow-up Visits between the Two Groups 
Variables IVB (n = 26) IVD (n = 26) P-value* 
Baseline BCVA (logMAR) 0.50 ± 0.13 0.52 ± 10 0.540 
BCVA at the 1-month follow-up (logMAR) 0.41 ± 0.12 0.44 ± 0.14 0.825 
BCVA at the 3-month follow-up (logMAR) 0.28 ± 0.0.9 0.31 ± 0.13 0.466 
BCVA at the 6-month follow-up (logMAR) 0.25 ± 0.1 0.29 ± 0.07 0.442 
* Based on a t-test; IVB = intravitreal bevacizumab, IVD = intravitreal diclofenac, logMAR = logarithm of the minimum angle of resolution 
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Figure 2: Comparison of Best-Corrected Visual Acuity (BCVA) at 6 Months of Follow-Up between the Two Groups based on the Number of Injections 
 
Table 4: Multivariate Linear Regression Analysis 
Variable Odds ratio (95% confidence interval) p value 
Number of injections 0.158 (0.17, 0.299) 0.029 
Baseline central macular thickness (µm) 0.0 (0.0, 0.001) 0.653 
Reduction in central macular thickness after the first injection (µm) 0.002 (0.0, 0.004) 0.017 
Stage of diabetic retinopathy (severe NPDR) 0.102 (-0.51, 255) 0.181 
HbA1c (mg/dL) -0.96 (-0.168, -0.24) 0.011 
The intravitreal bevacizumab (IVB) group was the reference parameter and the odds ratio of the intravitreal diclofenac (IVD) group was evaluated 
based on the IVB group. This analysis shows the effect of variables on final best-corrected visual acuity (BCVA) 
 
 
The number of injections and the reduction in CMT after 
the first injection (µm) and baseline HbA1c (mg/dL) were 
factors that had a significant impact on final BCVA. 
Macular Thickness and Volume 
The mean baseline CMT in the IVB group was 409.8 ± 
116.8 µm and 428.2 ± 94.4 µm in the IVD group. There 
was no significant difference between the two groups (P 
= 0.533). After 1 month, the CMT decreased to 386.1 ± 
101.2 µm in the IVB group and 406.1 ± 92.5 µm in the 
IVD group. After 3 months, the CMT was 355.4 ± 95.1 µm 
in the IVB group and 355.4 ± 95.1 µm in the IVD group. 
After 6 months, it was 348.4 ± 98.1 µm in the IVB group 
and 360.7 ± 83.1 µm in the IVD group. There was no 
statistically significant difference between the two 
groups at any time point (Table 5). 
At 6 months, the macular thickness change to baseline 
thickness was -59.6 ± 99.4 in the IVB group and -66.1 ± 
79.6 in the IVD group (P = 0.06 for the IVB groups and P = 
0.00 for the IVD group) (Table 5). Macular volume at 
baseline was 10.8 ± 1.23 mm
3
 in the IVB group and 10.91 
± 1.41 mm
3
 in the IVD group, which was reduced to 10.17 
± 1.04 mm
3
 and 10.38 ± 1.47 mm
3
, respectively, after 6 
months. Macular volume change from baseline to 6 
months was -0.53 ± 0.75 in the IVB group and -0.44 ± 
0.76 in the IVD group (P = 0.008 for the IVB group and P = 
0.002 for the IVD group) (Table 6). There was no 
significant difference between macular volumes in the 
two groups. The number of injections did not significantly 
affect macular thickness changes in both groups (Fig 3, 
Table 6). 
The IOP was measured in both groups at baseline and 1 
week after injection. The IOP was reduced in the IVD 
group from 16.1 mmHg to 14.3 mmHg (P = 0.013) (Table 
7). 
The IOP increased in the IVB group from 15.7 mmHg to 
16/4 mmHg but it was not statistically significant (P = 
0.3). IVD may reduce the IOP, which is a desirable effect 
for patients with diabetes who may have increased IOP 
due to many reasons. 
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Table 5: Comparison of Central Macular Thickness between the Two Groups in Follow-up Visits 
Variables IVB (n = 26) IVD (n = 26) P-value* 
Central macular thickness (µm) 416.8 ± 116.2 439.2 ± 94.4 0.533 
Central macular thickness at the 1-month follow-up (µm) 386.1 ± 101.2 406.1 ± 92.5 0.740 
Central macular thickness at the 3-month follow-up (µm) 355.4 ± 95.1 394.9 ± 87.8 0.462 
Central macular thickness at the 6-month follow-up (µm) 348.4 ± 98.1 360.9 ± 83.1 0.648 
Central macular thickness change at month 6 compared to baseline central 
macular thickness 
-59.6 ± 99.4 -66.1 ± 79.6  
P-value among groups ** 0.06 0.00  
* Based on a t-test, ** based on a paired t-test, IVB = intravitreal bevacizumab, IVD = intravitreal diclofenac 
 
 
Figure 3: Comparison of Central Macular Thickness at 6 Months of Follow-up between the Two Groups based on Number of Injections 
 
Table 6: Comparison of Macular Volume between the Two Groups in Follow-Up Visits 
Variables IVB (n = 26) IVD (n = 26) P-value* 
Macular volume (mm
3
) 10.8 ± 1.23 10.91 ± 1.41 0.411 
Macular volume at the 1-month follow-up (mm
3
) 10.63 ± 1.2 10.75 ± 1.65 0.853 
Macular volume at the 3-month follow-up (mm
3
) 10.22 ± 0.92 10.51 ± 1.61 0.606 
Macular volume at the 6-month follow-up (mm
3
) 10.17 ± 1.04 10.38 ± 1.47 0.621 
Macular volume change at month 6 compared to baseline macular 
volume 
-0.53 ± 0.75 -0.44 ± 0.76  
 p-value within ** 0.002 0.008  
* Based on a t-test, ** based on a paired t-test, IVB = intravitreal bevacizumab, IVD = intravitreal diclofenac 
 
Table 7: Comparison of Intraocular Pressure (IOP) between Baseline and Following the First Injection in Each Group 
Study group Baseline 1 week after injection p-value* 
IVD 16.1 ± 3.1 mmHg 14.3 ± 2.7 mmHg 0.031 
IVB 15.7 ± 2.9 mmHg 16.4 ± 4.1 mmHg 0.312 
* Based on a paired t-test 
 
DISCUSSION
Intravitreal injections are being progressively used for 
the treatment of diabetic retinopathy, especially DME. 
Several studies have shown their superiority to 
traditional methods [23]. There are different intravitreal 
drugs that can be used to stop the progression of 
diabetic retinopathy. It is important to understand the 
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underlying mechanism of diabetic retinopathy to choose 
the proper drug. Many studies support the idea of using 
anti-VEGF treatments for DME [3, 24]. The other rational 
theory to stop the inflammation pathway involves 
corticosteroids, which have been used for the treatment 
of DME [25-27]. Corticosteroids are capable of inhibiting 
both COX and 5-lypoxygenase pathways but have severe 
complications such as cataract formation and increased 
IOP [13, 14]. In this non-randomized comparative 
interventional case series, we chose NSAIDs. Another 
study has supported the unique ability of diclofenac to 
stop the lipoxygenase pathway. This unique quality of 
diclofenac makes it similar to corticosteroids and a 
potent member of the anti-inflammatory NSAIDs [28]. In 
previous studies, different types of NSAIDs have been 
used for the treatment of DME. For example, topical 
nepafenac has been shown to be effective for DME 
treatment [29]. After cataract surgery, topical 
bromofenac was also suitable for inhibition of cystoids 
macular edema (CME) in patients with diabetes [30]. In 
this study, we examined the intravitreal route of 
administration because of better penetration of NSAIDs 
to the posterior segment. Direct injection into the 
vitreous can enhance the therapeutic effect of drug 
because of longer drug entrapment in the vitreous, which 
prolongs the half-life of the drug. The results indicated 
that both anti-VEGF and NSAIDs improved visual acuity 
and decreased macular thickness and macular volume 
after intravitreal injection significantly. However, there 
was no statistically significant difference between the 
two groups. On the other hand, NSAIDs lowered the IOP 
after 1 week but anti-VEGF increased IOP during the 
same period. This rise of IOP was not significant. This 
study had a longer follow-up of patients and the results 
support those of previous studies by Soheilian et al., who 
showed visual improvement in DME and other causes of 
macular edema [18, 31]. Elbendary et al. also confirmed 
the beneficial use of intravitreal diclofenac in comparison 
to corticosteroids on macular edema in patients with 
diabetes by visual acuity improvement and macular 
thickness changes. They also showed that NSAIDs reduce 
IOP in IVD-treated patients [17]. Intravitreal injection of 
diclofenac has been useful in refractory diabetic macular 
edema, too [20, 21]. In patients with diabetes, topical 
diclofenac was able to decrease IOP after cataract 
surgery [32]. This effect was the same in diabetic 
retinopathy patients after intravitreal injection. The long-
term follow-up in this study is another strong point, 
which has overcome the limitation of previous studies 
with short sample size and short follow-up time because 
of the short half-life of IVD (only 2.87 h) [33]. In 2016, it 
was shown that combination of intravitreal diclofenac 
with intravitreal bevacizumab was superior to 
bevacizumab alone [34]. Intravitreal diclofenac is 
effective and safe for improving BCVA and decreasing 
central macular thickness in patients who had vascular 
accident of branch retinal vein occlusion (BRVO) with 
macular edema [35]. The repeated injection of 
intravitreal diclofenac has helped overcome the problem 
of short half-life. A 6-month follow-up can somehow 
ensure that NSAIDs are reliable drugs in the long term, 
too. Anti-VEGF drugs, the current choice for patients with 
DME, may be replaced by NSAIDs, which can improve the 
BCVA and decrease CMT at the same level, with the 
additional effect of IOP lowering. In the future, clinical 
trials longer follow-up periods with larger sample sizes 
will help decide whether NSAIDs can replace anti-VEGF 
drugs or be combined with other drugs. Future studies 
should address whether NSAIDs can decrease the need 
for repeated injections. The reduction in number of 
intravitreal injections is a very important outcome for 
patients that could enhance patient compliance with the 
therapy for diabetic retinopathy. For more precise 
comparison of IVB and IVD, a randomized clinical trial 
may be desirable. 
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